Cargando…
Pulmonary valve reconstruction for acquired pulmonary regurgitation in patients with treated congenital heart disease
OBJECTIVES: Pulmonary valve regurgitation is a common problem after relief of right ventricular outflow tract (RVOT) obstruction with a transannular patch. Pulmonary valve replacement with a homograft or xenograft is the routine treatment. Longevity of biological valves and the availability of homog...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10581336/ https://www.ncbi.nlm.nih.gov/pubmed/37341633 http://dx.doi.org/10.1093/icvts/ivad105 |
_version_ | 1785122120469053440 |
---|---|
author | Jussli-Melchers, Jill Hansen, Jan Hinnerk Scheewe, Jens Attmann, Tim Eide, Martin Logoteta, Jana Dütschke, Peter Salehi Ravesh, Mona Uebing, Anselm Voges, Inga |
author_facet | Jussli-Melchers, Jill Hansen, Jan Hinnerk Scheewe, Jens Attmann, Tim Eide, Martin Logoteta, Jana Dütschke, Peter Salehi Ravesh, Mona Uebing, Anselm Voges, Inga |
author_sort | Jussli-Melchers, Jill |
collection | PubMed |
description | OBJECTIVES: Pulmonary valve regurgitation is a common problem after relief of right ventricular outflow tract (RVOT) obstruction with a transannular patch. Pulmonary valve replacement with a homograft or xenograft is the routine treatment. Longevity of biological valves and the availability of homografts are limited. Alternatives to restore RVOT competence are evaluated. The goal of this study was to present intermediate-term results for pulmonary valve reconstruction (PVr) in patients with severe regurgitation. METHODS: PVr was performed in 24 patients (August 2006‒July 2018). We analysed perioperative data, pre- and postoperative cardiac magnetic resonance (CMR) imaging studies, freedom from valve replacement and risk factors for pulmonary valve dysfunction. RESULTS: The underlying diagnoses were tetralogy of Fallot (n = 18, 75%), pulmonary stenosis (n = 5, 20.8%) and the double outlet right ventricle post banding procedure (n = 1, 4.2%). The median age was 21.5 (14.8–23.7) years. Main (n = 9, 37.5%) and branch pulmonary artery procedures (n = 6, 25%) and surgery of the RVOT (n = 16, 30.2%) were often part of the reconstruction. The median follow-up after the operation was 8.0 (4.7–9.7) years. Freedom from valve failure was 96% at 2 and 90% at 5 years. The mean longevity of the reconstructive surgery was 9.9 years (95% confidence interval: 8.8–11.1 years). CMR before and 6 months after surgery showed a reduction in the regurgitation fraction [41% (33–55) vs 20% (18–27) P = 0.00] and of the indexed right ventricular end-diastolic volume [156 ml/m(2) (149–175) vs 116 ml/m(2) (100–143), P = 0.004]. Peak velocity across the pulmonary valve (determined by CMR) half a year after surgery was 2.0, unchanged. CONCLUSIONS: PVr can be achieved with acceptable intermediate-term results and may delay pulmonary valve replacement. |
format | Online Article Text |
id | pubmed-10581336 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-105813362023-10-18 Pulmonary valve reconstruction for acquired pulmonary regurgitation in patients with treated congenital heart disease Jussli-Melchers, Jill Hansen, Jan Hinnerk Scheewe, Jens Attmann, Tim Eide, Martin Logoteta, Jana Dütschke, Peter Salehi Ravesh, Mona Uebing, Anselm Voges, Inga Interdiscip Cardiovasc Thorac Surg Congenital Disease OBJECTIVES: Pulmonary valve regurgitation is a common problem after relief of right ventricular outflow tract (RVOT) obstruction with a transannular patch. Pulmonary valve replacement with a homograft or xenograft is the routine treatment. Longevity of biological valves and the availability of homografts are limited. Alternatives to restore RVOT competence are evaluated. The goal of this study was to present intermediate-term results for pulmonary valve reconstruction (PVr) in patients with severe regurgitation. METHODS: PVr was performed in 24 patients (August 2006‒July 2018). We analysed perioperative data, pre- and postoperative cardiac magnetic resonance (CMR) imaging studies, freedom from valve replacement and risk factors for pulmonary valve dysfunction. RESULTS: The underlying diagnoses were tetralogy of Fallot (n = 18, 75%), pulmonary stenosis (n = 5, 20.8%) and the double outlet right ventricle post banding procedure (n = 1, 4.2%). The median age was 21.5 (14.8–23.7) years. Main (n = 9, 37.5%) and branch pulmonary artery procedures (n = 6, 25%) and surgery of the RVOT (n = 16, 30.2%) were often part of the reconstruction. The median follow-up after the operation was 8.0 (4.7–9.7) years. Freedom from valve failure was 96% at 2 and 90% at 5 years. The mean longevity of the reconstructive surgery was 9.9 years (95% confidence interval: 8.8–11.1 years). CMR before and 6 months after surgery showed a reduction in the regurgitation fraction [41% (33–55) vs 20% (18–27) P = 0.00] and of the indexed right ventricular end-diastolic volume [156 ml/m(2) (149–175) vs 116 ml/m(2) (100–143), P = 0.004]. Peak velocity across the pulmonary valve (determined by CMR) half a year after surgery was 2.0, unchanged. CONCLUSIONS: PVr can be achieved with acceptable intermediate-term results and may delay pulmonary valve replacement. Oxford University Press 2023-06-21 /pmc/articles/PMC10581336/ /pubmed/37341633 http://dx.doi.org/10.1093/icvts/ivad105 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Congenital Disease Jussli-Melchers, Jill Hansen, Jan Hinnerk Scheewe, Jens Attmann, Tim Eide, Martin Logoteta, Jana Dütschke, Peter Salehi Ravesh, Mona Uebing, Anselm Voges, Inga Pulmonary valve reconstruction for acquired pulmonary regurgitation in patients with treated congenital heart disease |
title | Pulmonary valve reconstruction for acquired pulmonary regurgitation in patients with treated congenital heart disease |
title_full | Pulmonary valve reconstruction for acquired pulmonary regurgitation in patients with treated congenital heart disease |
title_fullStr | Pulmonary valve reconstruction for acquired pulmonary regurgitation in patients with treated congenital heart disease |
title_full_unstemmed | Pulmonary valve reconstruction for acquired pulmonary regurgitation in patients with treated congenital heart disease |
title_short | Pulmonary valve reconstruction for acquired pulmonary regurgitation in patients with treated congenital heart disease |
title_sort | pulmonary valve reconstruction for acquired pulmonary regurgitation in patients with treated congenital heart disease |
topic | Congenital Disease |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10581336/ https://www.ncbi.nlm.nih.gov/pubmed/37341633 http://dx.doi.org/10.1093/icvts/ivad105 |
work_keys_str_mv | AT jusslimelchersjill pulmonaryvalvereconstructionforacquiredpulmonaryregurgitationinpatientswithtreatedcongenitalheartdisease AT hansenjanhinnerk pulmonaryvalvereconstructionforacquiredpulmonaryregurgitationinpatientswithtreatedcongenitalheartdisease AT scheewejens pulmonaryvalvereconstructionforacquiredpulmonaryregurgitationinpatientswithtreatedcongenitalheartdisease AT attmanntim pulmonaryvalvereconstructionforacquiredpulmonaryregurgitationinpatientswithtreatedcongenitalheartdisease AT eidemartin pulmonaryvalvereconstructionforacquiredpulmonaryregurgitationinpatientswithtreatedcongenitalheartdisease AT logotetajana pulmonaryvalvereconstructionforacquiredpulmonaryregurgitationinpatientswithtreatedcongenitalheartdisease AT dutschkepeter pulmonaryvalvereconstructionforacquiredpulmonaryregurgitationinpatientswithtreatedcongenitalheartdisease AT salehiraveshmona pulmonaryvalvereconstructionforacquiredpulmonaryregurgitationinpatientswithtreatedcongenitalheartdisease AT uebinganselm pulmonaryvalvereconstructionforacquiredpulmonaryregurgitationinpatientswithtreatedcongenitalheartdisease AT vogesinga pulmonaryvalvereconstructionforacquiredpulmonaryregurgitationinpatientswithtreatedcongenitalheartdisease |